HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bazedoxifene

HCID 154257
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
198481-32-2
Standard SMILES
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12
InChIKey
UCJGJABZCDBEDK-UHFFFAOYSA-N
Molecular formula
C30H34N2O3
Average molar mass
470.6 g/mol
Monoisotopic mass
470.25694295

Overview

Bazedoxifene is a phenylindole.

Names & identifiers

Preferred name
Bazedoxifene
IUPAC
1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
English name
Bazedoxifene
Molecular formula
C30H34N2O3
Molecular weight
470.6

Names & synonyms

Bazedoxifene198481-32-2ConbrizaBazedoxifenoTSE-424bazedoxifenumQ16TT9C5BKWAY 1404241-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-DTXSID70173593TSE424
Show more names
Bazedoxifen1-(4-(2-(Azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-olCS-1993BatoxifeneBardoxifeneUnii-Q16tt9C5bkBAZEDOXIFENE BASE
1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1-((4-(2-(azepan-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol1-((4-(2-(azepan-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methylindol-5-olRefChem:116748DTXCID3096084G03XC02Viviant

Database identifiers

Properties

Computed structural properties

XLogP
6.1
Topological polar surface area
57.9 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
4
Rotatable bonds
7
Heavy atoms
35
Formal charge
0
Complexity
623

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsEMA approved medicines: Human medicine

Physicochemical properties

Melting point
98 · 98-102°
Boiling point
694.4 · 694.4±55.0 °C(Predicted)
Density
1.19 · 1.19
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
solubility
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
form
Solid
pka
10.12 · 10.12±0.15(Predicted)
color
White to Very Dark Beige
FDA UNII
16 TT9C5BK · Q16TT9C5BK
NCI Drug Dictionary
bazedoxifene
ATC code
3 XC02 · G03XC02

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesRepr. 1A (100%)

Toxicology

Adverse Effects · 1 item

Based on the results analyzed in placebo-controlled trials, the most frequent adverse effects associated with the combination of conjugated estrogens and bazedoxifene include muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain, oropharyngeal pain, neck pain, and dizziness.

Toxicity SummarySigns and Symptoms of Overdose

Safety data

hs_code
2933990099
Signal word
Danger
Symbol(GHS)
GHS08
Hazard statements
H360
Precautionary statements
P201-P202-P281-P308+P313-P405-P501

Chemistry & industry

Pharmacology

ATC Code · 2 items

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein Binding98-99%.
Mechanism of Action · 1 item

Bazedoxifene belongs to a class of compounds known as selective estrogen receptor modulators (SERMs). Bazedoxifene acts as both an oestrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone remodelling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures. Bazedoxifene functions primarily as an oestrogen-receptor antagonist in uterine and breast tissues.

Biological Half-Life~30 hours.
Metabolism/Metabolites · 1 item

Glucuronidation is the major metabolic pathway. After peroral application, bazedoxifene is metabolized by UDP-glucuronosyltransferases (UGTs) to bazedoxifene-4'-glucuronide (M4) and bazedoxifene-5-glucuronide (M5).Little or no cytochrome P450-mediated metabolism is evident. The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged active substance in plasma.

FDA Pharmacological Classification · 5 items

Q16TT9C5BK

BAZEDOXIFENE

Established Pharmacologic Class [EPC] - Estrogen Agonist/Antagonist

Mechanisms of Action [MoA] - Selective Estrogen Receptor Modulators

Bazedoxifene is an Estrogen Agonist/Antagonist. The mechanism of action of bazedoxifene is as a Selective Estrogen Receptor Modulator.

MeSH Pharmacological Classification · 2 items

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Related reactions

38 records
New reaction record
HRID 339140 reaction equation
HRID 339140As reactant
HRID 500290 reaction equation
HRID 500290As product
HRID 1047094 reaction equation
HRID 1047094As reactant
HRID 1503309 reaction equation
HRID 1503309As product
HRID 1503310 reaction equation
HRID 1503310As product
HRID 1503311 reaction equation
HRID 1503311As product
HRID 1503312 reaction equation
HRID 1503312As product
HRID 1503313 reaction equation
HRID 1503313As product
PreviousPage 1 of 5

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS
198481-32-2
PubChem CID
154257
DTXSID
DTXSID70173593
ChEMBL
CHEMBL46740
ChEBI
CHEBI:135947
UNII
Q16TT9C5BK
EC Number
805-732-1
Nikkaji
J1.561.275D
Comptox DTXSID
70173593 · DTXSID70173593
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
360 · H360
Precautionary statements
201 · P201-P202-P281-P308+P313-P405-P501
HS Code
2933990099 · 2933990099

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Absorption, Distribution and Excretion · 4 items

Bazedoxifene is rapidly absorbed with a tmax of approximately 2 hours and exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg. The absolute bioavailability of bazedoxifene is approximately 6%.

The major route of elimination of radio-labelled bazedoxifene is the faeces, and less than 1% of the dose is eliminated in urine.

Following intravenous administration of a 3 mg dose of bazedoxifene, the volume of distribution is 14.7 ± 3.9 l/kg.

The apparent oral clearance of bazedoxifene is approximately 4 to 5 l/h/kg.

Applications · 2 items

UsesBazedoxifene is an nonsteroidal selective estrogen receptor modulator (SERM). Bazedoxifene is used as an antiosteoporotic.

General DescriptionBazedoxifene, 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol (Viviant), was declared to be “approvable” bythe FDA in 2007 for the prevention of postmenopausalosteoporosis. As of mid-2009, final approval in the UnitedStates is still pending. Bazedoxifene was approved inEurope in 2009 for the treatment of post–menopausalosteoporosis.

Upstream & downstream products

Upstream raw materials

1H-Indol-5-ol, 1-[[4-(2-aminoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-1H-Azepine-2,7-dione, tetrahydro-1-[2-[4-[[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl]phenoxy]ethyl]-1H-Indol-5-ol, 2-[4-(acetyloxy)phenyl]-3-methyl-, 5-acetateAdipaldehyde1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole2-(4-hydroxyphenyl)-3-Methyl-1H-indol-5-ol4-[2-(1-Azepanyl)ethoxy]benzyl chloride HClHexamethyleneimine

Additional notes

DefinitionChEBI: Bazedoxifene is a phenylindole.